Korea Investment CORP Purchases New Stake in Stryker Corporation $SYK

Korea Investment CORP purchased a new stake in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 170,682 shares of the medical technology company’s stock, valued at approximately $53,738,000.

A number of other large investors have also added to or reduced their stakes in the company. Varma Mutual Pension Insurance Co lifted its position in Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after buying an additional 5,100 shares during the period. QRG Capital Management Inc. grew its position in shares of Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after buying an additional 4,186 shares during the period. Swedbank AB increased its stake in shares of Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after acquiring an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in shares of Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after acquiring an additional 6,367 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after acquiring an additional 199,863 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 665,370 shares of company stock worth $216,238,501 in the last three months. Insiders own 4.60% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analysts Set New Price Targets

Several equities research analysts recently commented on SYK shares. Barclays dropped their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on Stryker in a research report on Friday, May 1st. Piper Sandler cut their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, Citizens Jmp reduced their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Performance

Shares of SYK stock opened at $329.86 on Friday. The company has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company’s 50-day moving average is $326.99 and its 200 day moving average is $332.64.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.